Popular search terms:
Search Results Label
9 results found-
Seqirus | Meet Our Leadership
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.seqirus.us/our-company/leadership -
Gregg Sylvester
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.seqirus.us/our-company/leadership/gregg-sylvester -
Seqirus | About Us
Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.seqirus.us/our-company -
The University of Queensland CEPI and CSL partner on COVID 19 vaccine candidate
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
https://www.seqirus.us/news/the-university-of-queensland-cepi-and-csl-partner-on-covid-19-vaccine-candidate -
COVID19 Update
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/covid19-update -
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older
https://www.seqirus.us/news/be-fluent-partnership-shines-spotlight-on-importance-of-flu-prevention-in-seniors -
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
https://www.seqirus.us/news/seqirus-is-first-to-market-with-shipment-of-seasonal-influenza-vaccines-for-2016-2017-season -
Seqirus announces next major advancement in cell-based influenza vaccine technology
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.
https://www.seqirus.us/news/seqirus-announces-next-major-advancement-in-cell-based-influenza-vaccine-technology -
US Media Release Template Q3 2013
About Seqirus Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG.
https://www.seqirus.us/-/media/seqirus-us/news/franchise-shipment-press-release--71116final-530-pm.pdf